Join us as we explore the future of autonomous aviation with CEO Brandon Robinson of Horizon Aircraft and their groundbreaking Cavorite X7 eVTOL aircraft. Discover how advanced sensors and fly-by-wire systems are paving the way for a future where autonomous air travel could become the norm, offering benefits like bypassing ground traffic and improving safety and efficiency. With promising technical updates and progress on the horizon, Horizon Aircraft is confident in making its vision a reality.

Rogue Space Systems Corporation has been awarded over 1 million dollars for their groundbreaking satellite-characterization upgrades with the Contactless LAser Satellite Stethoscope (CLASS) project. This technology aims to improve space traffic management by identifying and diagnosing Resident-Space-Objects using a laser vibrometer. The success story highlights the impact of SBIR and STTR initiatives on small businesses, as Rogue's CEO and COO discuss the importance of this technology for their fleet of Orbots™ and in-space logistics services.

Join us in this episode as we dive into Panther Minerals Inc.'s strategic growth plans in the booming uranium market. With a focus on high-quality projects like Boulder Creek and Fireweed prospects, the company is utilizing advanced technology to identify key exploration areas. Learn about their recent acquisitions and successful fundraising efforts to support their expansion goals.

Join us in this episode as we discuss Panther Minerals Inc.'s strategic growth plans in the booming uranium market, projected to reach $11.38 billion by 2030. The company is actively expanding in North America, focusing on high-quality uranium projects like the Boulder Creek and Fireweed prospects. Utilizing advanced technology like satellite imagery and hyperspectral analysis, Panther Minerals is pinpointing high-potential areas for exploration and has secured permits for a five-year program.

Join us as we discuss Alzamend Neuro, Inc.'s partnership with Massachusetts General Hospital for a Phase II trial of a next-generation treatment for Major Depressive Disorder (MDD). Learn about the innovative approach of using AL001, a lithium-based therapeutic candidate, to address the symptoms of MDD. CEO Stephan Jackman shares his optimism for the potential of AL001 as a safer and more effective alternative for MDD treatment. Alzamend Neuro is also actively involved in Phase II trials for bipolar disorder and Alzheimer's disease, with Dr. Ovidiu Andronesi leading the way.

Join us as we explore Li-FT Power's focus on lithium exploration in Canada with CEO Francis MacDonald. Learn about the high concentrations of lithium found in the Yellowknife Lithium Project and the potential for discovery in Quebec. Discover how the Cali Project in the Northwest Territories positions Li-FT for growth in the near future.

In this episode, we discuss Alzamend Neuro, Inc.'s partnership with Massachusetts General Hospital for a Phase II clinical trial of AL001, a potential game-changer for bipolar disorder treatment. The study aims to establish AL001's safe, effective, and tolerable dosing requirements, potentially simplifying treatment regimens and improving patient compliance. We also explore the rising impact of mental health issues globally and how Alzamend Neuro is advancing new treatments for various conditions. Additionally, we cover BioLumic's innovative use of light to enhance inbred corn lines, with promising results and plans for commercialization in 2025.

Join us as we explore Theriva Biologics' innovative approach to oncolytic virus therapies, aimed at improving survival rates for difficult-to-treat cancers like brain tumors and pancreatic cancers. Learn about their leading candidate, VCN-01, and the promising results seen in clinical trials for various types of cancer. Discover how Theriva is pushing the boundaries with next-generation viruses like VCN-11 with Albumin Shield technology, paving the way for future advancements in cancer treatment.

In this episode, we discuss the rising prevalence of pancreatic cancer and the promising treatment being developed by Oncolytics Biotech Inc. called pelareorep. The GOBLET study is currently testing pelareorep in combination with mFOLFIRINOX and atezolizumab in newly diagnosed metastatic pancreatic cancer patients, with positive results in previous trials and Fast Track Designation from the FDA. This innovative therapy could offer new hope for pancreatic cancer patients and improve outcomes.

Today's episode covers the latest advancements in mental health treatment by MIRA Pharmaceuticals (NASDAQ: MIRA), with promising preclinical trial results for compounds MIRA-55 and Ketamir-2. MIRA-55 offers therapeutic benefits without side effects like increased appetite or paranoia, while Ketamir-2 targets treatment-resistant depression. With a focus on patient care, MIRA aims to improve access and affordability, potentially changing the standard of care for neurological and neuropsychiatric disorders. In other news, Doubleview Gold Corp has resumed drilling at the Hat Project in Northern British Columbia, utilizing technical and statistical models to improve grade and explore mineralization trends for a future Mineral Resource Estimate.